The International Working Group on the Diabetic Foot (IWGDF) has unveiled 2023 guidelines which now includes topical oxygen therapy as a positive adjunctive treatment recommendation.
The announcement, which occurred at the International Symposium on the Diabetic Foot (ISDF), puts the therapy in line with positive sentiment by the American Diabetes Association (ADA).
Oxygen therapy product developers such as AOTI will benefit from the recommendation. AOTI’s therapy uses cyclical pressurised oxygen that can be applied directly to a wound site. Amongst other indications – such as venous leg ulcers, burn wounds and pressure ulcers – diabetic foot ulcers (DFU) are a key chronic wound use of the products. Oxygen promotes faster and more durable healing, whilst compression reduces oedema and enhances vascular circulation.
According to the Oceanside, California-based company, its therapy is different to other topical oxygen techniques in that it “provides a multimodality treatment, combining higher pressure oxygen delivery with non-contact cyclical compression and humidity, applied by the patient at home.” In a study, AOTI therapy was shown to reduce hospitalisations and amputations.
“We are thrilled to see the IWGDF follow the lead of the ADA in recognizing the overwhelming body of clinical evidence now supporting topical oxygen therapy in healing DFUs,” said Dr. Mike Griffiths, CEO and President of AOTI.
Research by GlobalData valued the oxygen therapy devices market at $440m in 2022. Primary factors driving the market are increasing incidences of acute and chronic wounds and increasing numbers of patients living from diabetes. In July 2022, wound care company MolecuLight reported boosted healing in DFUs with use of its autofluorescence imaging device to view bacterial presence.